In a nutshell This study evaluated if there were any clinical indicators to identify which patients with advanced melanoma would benefit from immune checkpoint blocker (ICB) therapy. The data showed that blood LDH levels, the extent of disease, number of white blood cells, and immune-related side effects were all associated with better...
Read More
In a nutshell This study was carried out to examine the safety and effectiveness of pyrotinib (Irene) in combination with vinorelbine (Navelibine) is in treating metastatic breast cancer (BC). The authors found that this treatment combination showed promising results and was well tolerated in these patients. Some background BC is...
Read More
In a nutshell This study compared the effectiveness of docetaxel (DOC; Taxotere) to abiraterone (ABI; Zytiga) and assessed possible predictive markers of progression-free survival (PFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC). The authors concluded that under real-world conditions, ABI was associated with...
Read More
In a nutshell This study reported the long-term effectiveness and safety outcomes of apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). The data showed that this combination improved survival, delayed castration resistance, and maintained the...
Read More
In a nutshell This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer (mTNBC). The data showed that SG significantly improved the survival outcomes of these patients compared to chemotherapy. Some background...
Read More
In a nutshell This study compared the survival and safety outcomes of pembrolizumab (Keytruda; PEM) plus enzalutamide (Xtandi; ENZ) combination versus pembrolizumab alone in patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that PEM plus ENZ combination was associated with increased survival...
Read More
In a nutshell This study evaluated the effects and outcomes of adding everolimus (EVE; Afinitor) plus letrozole (LET; Femara) to hormonal therapy for the treatment of premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (BC). The data showed that the combination of EVE+LET improved survival...
Read More
In a nutshell This trial was carried out to assess the effectiveness of EGFR-tyrosine kinase inhibitors (TKIs) with stereotactic body radiation therapy (SBRT) in advanced non-small-cell lung cancer (NSCLC). The authors found that TKIs plus SBRT improved the survival without disease worsening for these patients. Some background Lung cancer...
Read More
In a nutshell This review was carried out to analyze the effectiveness and safety of EGFR tyrosine kinase inhibitors (TKIs) plus chemotherapy (CT) versus EGFR-TKIs alone as a treatment for advanced non-small-cell lung cancer (NSCLC) that is EGFR-positive. The authors found that EGFR-TKIs and CT treatment improved survival for these patients while...
Read More
In a nutshell The authors evaluated the safety and effectiveness of paclitaxel (Taxol) in combination with alisertib (MLN8237) for the treatment of advanced breast cancer (BC). The authors observed that a weekly, reduced dose of paclitaxel combined with alisertib improved the survival without cancer worsening in these...
Read More
In a nutshell This study investigated the effectiveness and safety outcomes of radiotherapy given at the same time (concurrent chemoradiotherapy; cCRT) or after chemotherapy (sequential chemoradiotherapy; sCRT) for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). The data showed that cCRT improved the long-term...
Read More
In a nutshell This trial looked at nivolumab (Opdivo) plus ipilimumab (Yervoy) combined with 2 cycles of chemotherapy as treatment for patients with non-small cell lung cancer (NSCLC). The authors found that this combination provided an improved overall survival versus chemotherapy-only regimens. Some background NSCLC is responsible for 85% of...
Read More
